11 April 2024
11 April 2024
Amylyx pulled Relyvrio from the ALS market on 4 April but is continuing to investigate the candidate in other indications.
The current downsizing is separate from a company restructuring programme, which could see the dismissal of up to 8,000 employees.
Ocugen will soon be initiating a Phase III trial of its gene therapy candidate OCU400 for retinitis pigmentosa (RP).
Signati aims to take the next big step in vasectomies by offering men a safer and quicker option for family planning.
The 21,000 subject-study demonstrated a reduction in psychiatric-related hospitalisations following the test.
Transgene and NEC also plan to start the Phase II extension for its individualised cancer vaccine, TG4050, in Q2 this year.
Two-thirds of the patients who self-administered one or more etripamil doses experienced symptom relief within an hour.
ALKS 2680 was found to be well tolerated in subject group populations at all of the doses tested.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
